IL-PRICEFX
16.12.2020 15:32:08 CET | Business Wire | Press release
Pricefx , the global leader in cloud-native pricing software, today launched Velo, a unique offering for companies to maximize value on large deal negotiations. Designed to manage the largest transactional relationships in each business, Velo is the industry’s first solution specifically focused on helping sellers to prepare for, and win, profit-maximizing outcomes on large contract negotiations, bids, proposals and sourcing events. Combining a proven deal negotiation methodology with innovative technology for value estimation and leverage optimization, Velo now gives businesses the analytical insights, structured process and workflow automation to negotiate highly customized deals with confidence.
For many large B2B companies, the top 5-10% of their customers make up more than 50% of revenue. The agreements with those customers are essential to the company’s survival. With changes in demand, both buyers and sellers seek to optimize their largest positions as contracts and commitments naturally expire or get adjusted. Buyers often use powerful procurement platforms to optimize their position. With Velo, companies can now equip themselves with an equally powerful package of technology and strategy to maximize value, optimize leverage and negotiate to win.
“Companies have traditionally relied on spreadsheets and manual processes, without collaborative tools, thus leaving potential negotiation power unknown,” said Marcin Cichon, CEO and co-founder at Pricefx. “We are giving businesses a powerful, new way to manage large, complex deals, leveling the playing field in negotiations, and improving outcomes. Tribal wisdom and outdated CPQ technology are no match for the capabilities of Velo.”
“Procurement organizations continue to attack the profit and value positions of their largest suppliers,” said Brian Sharp, Chief Revenue Officer for Profit Velocity. “Category-by-category, sellers face a withering storm of sourcing event approaches with software and services geared toward depleting supplier profits and value. Velo is the first solution to re-balance the playing field so that suppliers can capture their fair share of the value they create for their largest customers.”
Pairing Pricefx ValueEstimator and LargeDealOptimizer modules with the proven methodology from partner Profit Velocity, Velo is a one-of-a-kind strategic software solution to maximize profitability and leverage in large deals. It pairs this software with a proven process-centered methodology, leveraging leading-edge scenario-based negotiation playbooks and a team of negotiation experts who have managed over 400 large complex deals with cumulative recurring revenues exceeding $8 Billion/year across a multitude of industry verticals.
LargeDealOptimizer facilitates the planning of large, complex deals with guidance and contextual information to support the negotiation of monolithic deals in one, central location. It manages deal teams through the workflow of establishing opening positions, anticipating buyer objections and counter-proposals, while aligning the team with their leadership’s objectives and governance. Efficiently streamlining, organizing, and approving complex customer transactions within the Pricefx platform, LargeDealOptimizer enables organizations to get the most value and profit from the customers that generate much of their revenue.
ValueEstimator enables companies to assess their differential competitive value based on the actual customer-based decision drivers. It establishes value-based pricing while enabling that value to be communicated when a price is set for a customer quote or proposal.
Velo provides a proven, immersive and agile service led by world-class negotiation experts, assuring business leaders and P&L owners that each deal team is ready to negotiate-to-win. While every large deal is customized by their very nature, the Velo solution provides a repeatable process-centered approach which fully integrates the new software tools. Early customer reviews of Velo say that Pricefx is offering “a unique new capability that connects its powerful price optimization engine to customer value data. We've waited a long time for this – a huge breakthrough for pricing leaders.”
Velo is easy-to-deploy and can be delivered one deal at-a-time or through a subscription-based approach to support the highest stakes deals. Historically businesses have consistently grown the profitability of their large customer transactions by an average of 440 basis points per deal by leveraging the Velo software and methodology.
Availability
Velo is available now and interested parties can learn more at www.hellovelo.com
.
About Profit Velocity Solutions LLC
A San Francisco-based data analytics software company, Profit Velocity has pioneered the use of time-based profit data analytics that enable the management teams of large manufacturers to fine-tune their mix of customers and products and unlock significant investor gains. With its unique profit data visualizations and instant what-if planning, Profit Velocity’s profit information platform turns readily available data into potent new insights that allow decision-makers to isolate and capture gains previously buried in an ocean of corporate data. Profit Velocity has served manufacturers, large and small, across North America, Asia, and Europe. For more information, please visit www.profitvelocity.com
.
About Pricefx
Established in 2011 in Germany, Pricefx is the global leader in SaaS pricing software, offering a comprehensive suite of solutions that are fast to implement, flexible to configure and customize, and friendly to learn and use. Pricefx delivers a complete price optimization and management platform based on native cloud architecture, providing industry leading time to value and total cost of ownership advantages to customers. Their innovative solution works for both B2B and B2C enterprises of any size, in any industry, in any part of the world. Pricefx’s business model is entirely based on the satisfaction and loyalty of its customers. Today, Pricefx delivers Passion for Pricing to more than 100 customers in more than 37 countries worldwide. For more information, please visit www.pricefx.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201216005113/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
